Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitiperstat (AZD4831) in cardiomyopathy and heart failure with reduced ejection fraction
2022-003797-23Phase 2Completed
- Sponsor
- Philipps-Universität Marburg
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ischaemic cardiomyopathy (ICM), Non-Ischaemic Cardiomyopathy (NICM), heart failure with reduced ejection fraction (HFrEF) and 1 more comparing Mitiperstat (AZD4831) with Placebo (2 arms). Primary endpoint: Change in log NT-proBNP levels from baseline to week 12. Started Jan 2023; status: completed.
02
Drugs
mitiperstat
03
Conditions
ischaemic cardiomyopathy (ICM)Non-Ischaemic Cardiomyopathy (NICM)heart failure with reduced ejection fraction (HFrEF)heart failure (HF)
Beyond the preview
Go deeper on 2022-003797-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003797-23.